Cefsulodin kinetics in renal impairment
- PMID: 7075110
- DOI: 10.1038/clpt.1982.84
Cefsulodin kinetics in renal impairment
Abstract
Cefsulodin kinetics were determined after a 500-mg dose to normal subjects and patients with varying degrees of renal insufficiency, including those requiring hemodialysis. Elimination kinetics were described by a two-compartment model. Steady-state volume of distribution was 0.26 l/kg regardless of renal function. When glomerular filtration rate (GFR) was more than 80 ml/min, elimination half-life (t1/2) was 1.9 hr, total body clearance (ClT) was 2.01 ml/kg/min, and renal clearance (ClR) was 1.09 ml/kg/ in. When GFR ranged from 79 to 53 ml/min, t1/2 was 2.9 hr, ClT was 1.17 ml/kg/min, and ClR was 0.65 ml/kg/min. In subjects with moderate renal failure in whom GFR was 32 to 22 ml/min, t1/2 was 5.7 hr, Clt was 0.66 ml/kg/min, and ClR was 0.26 ml/kg/min. In anuric patients t1/2 was 13.0 hr. and ClT was 0.19 ml/kg/min or 9.5% of ClT in normal subjects. There was a linear relationship between ClT and GFR such that ClT = 0.19 + 0.017 GFR (r = 0.95). During hemodialysis the average plasma flow was 122 ml/min, dialyzer plasma clearance was 50.9 ml/min, plasma drug concentration was reduced by 60%, and t1/2 fell to 2.1 hr. After dialysis the elimination rate appeared to return to that in nondialysis studies. Therefore, renal failure reduces the ClT of cefsulodin. In hemodialysis patients the maintenance dose of cefsulodin should be reduced to 10% of normal and 60% of the dose should be given after hemodialysis.
Similar articles
-
Cefsulodin pharmacokinetics in patients with various degrees of renal function.Antimicrob Agents Chemother. 1983 Mar;23(3):369-73. doi: 10.1128/AAC.23.3.369. Antimicrob Agents Chemother. 1983. PMID: 6847169 Free PMC article.
-
Kinetics of cefsulodin in patients with renal impairment.Rev Infect Dis. 1984 Sep-Oct;6 Suppl 3:S689-97. doi: 10.1093/clinids/6.supplement_3.s689. Rev Infect Dis. 1984. PMID: 6571338
-
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.Antimicrob Agents Chemother. 2018 Feb 23;62(3):e02103-17. doi: 10.1128/AAC.02103-17. Print 2018 Mar. Antimicrob Agents Chemother. 2018. PMID: 29311069 Free PMC article. Clinical Trial.
-
Pharmacokinetics of cephalosporins in patients with normal or reduced renal function.J Infect Dis. 1978 May;137 Suppl:S88-S99. doi: 10.1093/infdis/137.supplement.s88. J Infect Dis. 1978. PMID: 349098 Review.
-
Renal disease and drug metabolism: an overview.Am J Kidney Dis. 1986 Jul;8(1):7-17. doi: 10.1016/s0272-6386(86)80148-2. Am J Kidney Dis. 1986. PMID: 3524205 Review.
Cited by
-
Pharmacokinetics of cefotiam and cefsulodin after simultaneous administration to patients with impaired renal function.Antimicrob Agents Chemother. 1984 Sep;26(3):368-72. doi: 10.1128/AAC.26.3.368. Antimicrob Agents Chemother. 1984. PMID: 6095754 Free PMC article.
-
Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis.Clin Transl Sci. 2017 Sep;10(5):395-403. doi: 10.1111/cts.12481. Epub 2017 Jul 4. Clin Transl Sci. 2017. PMID: 28675584 Free PMC article.
-
Clinical pharmacokinetics of diacerein.Clin Pharmacokinet. 1998 Nov;35(5):347-59. doi: 10.2165/00003088-199835050-00002. Clin Pharmacokinet. 1998. PMID: 9839088 Review.
-
Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.Clin Pharmacokinet. 1984 Jan-Feb;9(1):42-66. doi: 10.2165/00003088-198409010-00003. Clin Pharmacokinet. 1984. PMID: 6362952 Review.
-
Cefsulodin pharmacokinetics in patients with various degrees of renal function.Antimicrob Agents Chemother. 1983 Mar;23(3):369-73. doi: 10.1128/AAC.23.3.369. Antimicrob Agents Chemother. 1983. PMID: 6847169 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical